by Chu W-Y, Singh OP, Sundar S, Pandey K, Das P, Mondal D, Younis BM, Musa AM, Kumar Singh AK, Verma DK, Chaubey R, Kumari P, Chakravarty J, Madhukar M, Topno RK, Kumar A, Kumar V, Rashid U, Maruf S, Ghosh P, Saeed MA, Khalil EAG, Ahmed AE, Ali MA, Noureldin A, Roseboom IC, Moreno J, Sanchez C, Bernardo L, Solana J, Torres A, Raja S, Rode J, Carrillo E, Alves F, Dorlo TPC. International Journal of Antimicrobial Agents 2026;107713. doi: 10.1016/j.ijantimicag.2026.107713
Summary: Treatment regimens and clinical outcomes for post-kala-azar dermal leishmaniasis (PKDL) vary across South Asia and Eastern Africa. The authors of this manuscript evaluated the skin target site pharmacokinetics (PK) of miltefosine, liposomal amphotericin B (LAmB), and paromomycin, and associated pharmacodynamics (PD) on skin parasite reduction and lesion healing, to determine PK/PD factors driving regional differences in clinical outcomes. Similar skin PK target attainment and relative parasite reduction were achieved for all regimens. Regional differences in parasite load and lesion score at baseline, and lesion healing rates, suggest disease presentation is the primary factor affecting clinical outcomes.
The post Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis first appeared on DNDi.